Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2000-05-17
2002-07-16
Stucker, Jeffrey (Department: 1647)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023100, C435S069100, C435S070100, C435S320100, C435S325000
Reexamination Certificate
active
06420544
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to newly identified polypeptides and polynucleotides encoding such polypeptides, to their use in identifying compounds that may be agonists and/or antagonists that are potentially useful in therapy, and to production of such polypeptides and polynucleotides.
BACKGROUND OF THE INVENTION
The drug discovery process is currently undergoing a fundamental revolution as it embraces ‘functional genomics’, that is, high throughput genome- or gene-based biology. This approach is rapidly superseding earlier approaches based on ‘positional cloning’. A phenotype, that is a biological function or genetic disease, would be identified and this would then be tracked back to the responsible gene, based on its genetic map position.
Functional genomics relies heavily on the various tools of bioinformatics to identify gene sequences of potential interest from the many molecular biology databases now available. There is a continuing need to identify and characterise further genes and their related polypeptides/proteins, as targets for drug discovery.
Multi-specific drug transporters are present in cells having a barrier function such as intestinal epithelial and brain microvessel endothelial cells. Other tissues, for example, liver and kidney, also contain multi-specific transporters that can mediate the excretion of drugs and metabolites. Information gained from using multi-specific transporters such as the mouse OATP5 gene product in cell based, membrane-based, binding or other assays could enhance drug formulation, selection of formulation excipients, and compound design.
SUMMARY OF THE INVENTION The present invention relates to mouse OATP5, in particular mouse OATP5 polypeptides and mouse OATP5 polynucleotides, recombinant materials and methods for their production. In another aspect, the invention relates to methods for identifying agonists and antagonists/inhibitors of the mouse OATP5 gene. This invention further relates to the generation of in vitro and in vivo comparison data relating to the polynucleotides and polypeptides in order to predict oral absorption and pharmacokinetics in man of compounds that either agonise or antagonise the biological activity of such polynucleotides or polypeptides. Such a comparison of data will enable the selection of drugs with optimal pharmacokinetics in man, i.e., good oral bioavailability, blood-brain barrier penetration, plasma half life, and minimum drug interaction.
The present invention further relates to methods for creating transgenic animals, which overexpress or underexpress or have regulatable expression of a mouse OATP5 gene and “knock-out” animals, preferably mice, in which an animal no longer expresses a mouse OATP5 gene. Furthermore, this invention relates to transgenic and knock-out animals obtained by using these methods. Such animal models are expected to provide valuable insight into the potential pharmacological and toxicological effects in humans of compounds that are discovered by the aforementioned screening methods as well as other methods. An understanding of how a mouse OATP5 gene functions in these animal models is expected to provide an insight into treating and preventing human diseases including, but not limited to cancer, inflammation, cardiovascular disease, central nervous system disorders, auto-immune disease, and kidney and liver disease, hereinafter referred to as “the Diseases”, among others.
In a further aspect, the invention relates to methods for identifying agonists and antagonists/inhibitors using the materials provided by the invention, and treating conditions associated with OATP5 imbalance in humans with the identified compounds. Another embodiment of this invention provides for methods to identify compounds that neither agonise nor antagonise OATP5. This invention further relates to the generation of in vitro and in vivo comparison data to predict oral absorption and pharmacokinetics in man. Such a comparison of data will enable selection of drugs with optimal pharmacokinetics in man, i.e., good oral bioavailability, brain penetration, plasma half life, and minimum drug interaction.
REFERENCES:
patent: WO 98/53064 (1998-11-01), None
Sambrook et al., Molecular Cloning—A Laboratory Manual, 2nd Edition, 1989, 16.20-16.67.*
Choudhuri et al. (2001), Cloning, Expression and Ontogeny of Mouse Organic Anion Transporting Polypeptide-5 a Kidney-Specific Organic Anion Transporter, Biochem. and Biophy. Res. Comm., 280, pp. 92-98.*
Altschul, et al., “Basic Local Alignment Search Tool”, J. Mol. Biol., vol. 215, pp. 403-410 (1990).
Hosoyamada, et al., “Molecular cloning and functional expression of a multispecific organic anion Transporter from human kidney”, Am. J. Physiol., vol. 276, pp. 122-128 (1999).
Lopez-Nieto, et al., “Molecular Cloning and Characterization of NKT, a Gene Product Related to the Organic Cation Transporter Family That Is Almost Exclusively Expressed in the Kidney”, The Journal of Biological Chemistry, vol. 272, pp. 6471-6478 (1997).
Sekine, et al., “Expression Cloning and Characterization of a Novel Multispecific Organic Anion Transporter”, The Journal of Biological Chemistry, vol. 272, pp. 18526-18529 (1997).
GenBank Accession No. U52842, Lopez-Nieto, et al., Submitted (Mar. 27, 1996).
Sweet, et al., “Expression Cloning and Characterization of ROAT1”, The Journal of Biological Chemistry, vol. 272, pp. 30088-30095 (1997).
Ellens Harma
Feild John
Yue Lin
Ratner & Prestia
Seharaseyon Jegatheesan
SmithKline Beecham Corporation
Stucker Jeffrey
LandOfFree
Polynucleotide and polypeptide sequences encoding murine... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polynucleotide and polypeptide sequences encoding murine..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polynucleotide and polypeptide sequences encoding murine... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2917481